Clinical trials: Endometrial Disease
Endometrial Cancer
Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer
Endometrial cancer is the most common pelvic gynecological cancer in so-called developed countries, with 320,000 new cases annually, including more than 1,500 in Belgium. It preferentially affects postmenopausal women.
- Trial name
- NCT03115593
- Testing
- Blind biopsy with a pipette, Targeted biopsy using hysteroscopy
- Where
- 4 sites in Belgium, France
- Sponsor
- Brugmann University Hospital
Endometrial Cancer
ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy
The goal of this observational study is to evaluate whether combining postoperative circulating tumor DNA (ctDNA) testing with a novel genomic risk model can better predict recurrence risk and guide adjuvant therapy decisions in…
- Trial name
- NCT07681414
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Guizhou Provincial People's Hospital
Endometrial Cancer
European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III
Intermediate/high risk endometrial cancer shows locoregional recurrence rates up to 20%. Also in so called low-risk disease 5-10% incidence of nodal metastasis is reported.
- Trial name
- PMMR (NCT04504006)
- Testing
- Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Dr. Paul Buderath
Heavy Menstrual Bleeding
Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device
All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or…
- Trial name
- NCT02449304
- Testing
- Endometrial ablation (4th gen)
- Volunteers
- 50 people
- Sponsor
- Birmingham Women's NHS Foundation Trust
Endometrial Cancer, Mismatch Repair-Proficient
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
- Conditions
- Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer
- Trial name
- NCT05263492
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Virginia Commonwealth University
Women With Suspected or Confirmed Gynecological Disease
DOvEEgene Fleur: New Uterine Sampling Tool
This study is related to a previous study from the same group which started in 2014 (NTC02288676, McGill REB A08-M79-13B, MUHC REB 2020-5945) to develop a clinically implementable screening test -DovEEgene: developing and…
- Trial name
- NCT04258449
- Testing
- DOvEEgene Fleur Sampling
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University
Polycystic Ovary Syndrome, Infertility
Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)
Progestin-induced endometrial shedding (PIES) followed by clomiphene citrate is fertility treatment of choice in anovulatory women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT01718444
- Testing
- Progestin, Clomiphene Citrate
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Illinois Chicago
Leiomyosarcoma, Endometrial Stromal Tumors
Vorinostat (SAHA) in Uterine Sarcoma
Uterine sarcomas are rare tumors with a poor prognosis. The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat…
- Conditions
- Leiomyosarcoma, Endometrial Stromal Tumors, Carcinosarcomas Uterine
- Trial name
- NCT03509207
- Testing
- Vorinostat Oral Capsule
- Where
- Austria
- Volunteers
- 3 people
- Sponsor
- Medical University of Graz
Endometrial Neoplasms, Ovarian Neoplasms
Questionnaire Study for Gynecological Cancer Survivors
The purpose of this study is to evaluate the quality of life of long-term gynecologic cancer survivors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms
- Trial name
- NCT00391664
- Testing
- Psychosocial
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- U.S. Army Medical Research and Development Command
Neoplasms, Colorectal, Neoplasms
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Trial name
- NCT07213609
- Testing
- GSK5460025
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy.
- Trial name
- NCT03671811
- Testing
- Megestrol Acetate, Pterostilbene
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
- Trial name
- NCT03212404
- Testing
- CK-301 (cosibelimab)
- Where
- 48 sites in Australia, France and 7 more
- Volunteers
- 272 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Endometrial Cancer
Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation
Rationale: Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer (EC).
- Trial name
- ENDORISK-I (NCT07200466)
- Testing
- ENDORISK personalized risk assesment for lymph node metastases in endometrial cancer.
- Where
- 14 sites in Netherlands
- Volunteers
- 735 people
- Sponsor
- Radboud University Medical Center
Asherman's Syndrome, Thin Endometrial Lining
Senescent Endometrial Cells in Patients With Thin Endometrial Lining
The goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives.
- Conditions
- Asherman's Syndrome, Thin Endometrial Lining, Cell Senescence
- Trial name
- NCT06450301
- Testing
- Endometrial Biopsy
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Trio Fertility
Abnormal Uterine Bleeding, Dysmenorrhea
Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study
The objective of this study is to assess the efficacy of an implantable etonogestrel device in reducing hysterectomy rate in patients with a failed endometrial ablation.
- Trial name
- FEATS (NCT05227456)
- Testing
- Etonogestrel 68mg implant
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
This research project addresses the urgent need for novel therapeutic strategies to overcome chemotherapy resistance and mitigate chemotherapy-induced peripheral neuropathy (CIPN) in patients with recurrent ovarian and…
- Trial name
- NCT06620029
- Testing
- BMX-001, Paclitaxel (Taxol)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- BioMimetix JV, LLC
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Endometrial Cancer
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006377
- Testing
- carboplatin, doxorubicin hydrochloride, paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Fibrosarcoma, Adult Leiomyosarcoma
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma.
- Conditions
- Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00659360
- Testing
- saracatinib
- Where
- 4 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Bleeding, Uterine Cancer
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression
The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor.
- Conditions
- Uterine Bleeding, Uterine Cancer, Uterine Neoplasms, Endometrial Cancer
- Trial name
- MIRA (NCT07581288)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.